<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34752923</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>161</Volume><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol Dis</ISOAbbreviation></Journal><ArticleTitle>Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology.</ArticleTitle><Pagination><StartPage>105548</StartPage><MedlinePgn>105548</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2021.105548</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(21)00297-7</ELocationID><Abstract><AbstractText>TDP-43 pathology is a hallmark of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal lobar degeneration (FTLD). Namely, both diseases feature aggregated and phosphorylated TDP-43 containing inclusions in the cytoplasm and a loss of nuclear TDP-43 in affected neurons. It has been reported that tau tubulin kinase (TTBK)1/2 phosphorylate TDP-43 and TTBK1/2 overexpression induced neuronal loss and behavioral deficits in a C. elegans model of ALS. Here we aimed to elucidate the molecular mechanisms of TTBK1 in TDP-43 pathology. TTBK1 levels were observed to be elevated in ALS patients' post-mortem motor cortex. Also, TTBK1 was found to phosphorylate TDP-43 at disease-relevant sites in vitro directly, and this phosphorylation accelerated TDP-43 formation of high molecular species. Overexpression of TTBK1 in mammalian cells induced TDP-43 phosphorylation and the construction of high molecular species, concurrent with TDP-43 mis-localization and cytoplasmic inclusions. In addition, when TTBK1 was knocked down or pharmacologically inhibited, TDP-43 phosphorylation and aggregation were significantly alleviated. Functionally, TTBK1 knockdown could rescue TDP-43 overexpression-induced neurite and neuronal loss in iPSC-derived GABAergic neurons. These findings suggest that phosphorylation plays a critical role in the pathogenesis of TDP-43 pathology and that TTBK1 inhibition may have therapeutic potential for the treatment of ALS and FTLD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Merck Sharp &amp; Dohme Corp. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA. Electronic address: yuan.tian1@merck.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jablonski</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yinghui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugam</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koglin</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mass Spectrometry &amp; Biophysics, MRL, Merck &amp; Co., Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stachel</LastName><ForeName>Shawn J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemistry, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Genetics and Pharmacogenomics, MRL, Merck &amp; Co., Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uslaner</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmentier-Batteur</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuroscience, MRL, Merck &amp; Co., Inc, 770 Sumneytown Pike, West Point, PA 19486, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.11</RegistryNumber><NameOfSubstance UI="C095903">tau-tubulin kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017173" MajorTopicYN="N">Caenorhabditis elegans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Aggregation</Keyword><Keyword MajorTopicYN="N">FTLD</Keyword><Keyword MajorTopicYN="N">Mis-localization</Keyword><Keyword MajorTopicYN="N">Pathology</Keyword><Keyword MajorTopicYN="N">Phosphorylation</Keyword><Keyword MajorTopicYN="N">Postmortem</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TTBK1</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34752923</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2021.105548</ArticleId><ArticleId IdType="pii">S0969-9961(21)00297-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>